Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

May 18th 2020

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Larotrectinib Benefits Patients With NTRK Fusions, Regardless of Pretreatment or Performance Status

May 11th 2020

David S. Hong, MD, discusses the results of these analyses with larotrectinib in patients with NTRK alterations.

FDA Approves myChoice CDx as Companion Diagnostic for Olaparib in Ovarian Cancer

May 11th 2020

The FDA has approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with positive homologous recombination deficiency status, making them eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.

FDA Approves myChoice CDx as Companion Diagnostic for Olaparib in Ovarian Cancer

May 11th 2020

The FDA has approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with positive homologous recombination deficiency status, making them eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.

Oncology Clinical Trials Should Reflect Molecular Advances, Real-World Patients

May 11th 2020

From the earliest moments of medical school instruction, through residency and fellowship training, physicians are taught the primacy of the randomized phase 3 trial in the hierarchy of evidence-based medicine.

Dr. Hughes on Mutational Risk in Oncology

May 9th 2020

Kevin Hughes, MD, discusses mutational risk in oncology.

Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors

May 8th 2020

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Defactinib Plus RAF/MEK Inhibitor Combo Active in KRAS-Driven Cancers

May 5th 2020

Udai Banerji, discusses the rationale for a phase 1 trial, the potential implications of these data, and future studies in development.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Despite Advances, Genetic Testing Remains Underutilized in Breast Cancer

April 30th 2020

Kevin Hughes, MD, highlights the need for widespread implementation of genetic testing in breast cancer.

Blood Test Is Feasible for Early Detection Across Multiple Cancers

April 29th 2020

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

Larotrectinib Approved in UK for NTRK+ Cancers

April 22nd 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended larotrectinib for the treatment of adult and pediatric patients with advanced NTRK fusion–positive solid tumors.

FDA Approves FoundationOne CDx as Pemigatinib Companion Diagnostic in FGFR2+ Cholangiocarcinoma

April 21st 2020

The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib, which the agency recently approved for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic FGFR2+ cholangiocarcinoma.

Dr. Husain on the Evolution of Liquid Biopsies in Lung Cancer

April 20th 2020

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Dr. Hudson on the Utility of Liquid Biopsy in Lung Cancer

April 16th 2020

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Genomic Profiling Shows Clinical Utility in Select Sarcomas

April 15th 2020

Comprehensive genomic profiling can be successfully performed in the majority of patients with sarcoma, depending on the tumor location and tissue subtype, which can impact treatment decisions and patient outcomes.

Innovative plasmaMATCH Trial Displays Feasibility With ctDNA in Breast Cancer

April 15th 2020

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

Dr. Alshaygy on Precision Medicine Research in TGCT

April 15th 2020

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

Dr. Dimou on Progress Made in ALK+ Lung Cancer Treatment

April 15th 2020

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

NEXT PAGE
PREVIOUS PAGE